Ucommune calls extraordinary general meeting of shareholders
Bitget2026/10/08 12:18Ucommune will hold an extraordinary general meeting in Beijing on Nov. 9, 2026. Shareholders will vote on a potential reverse share split triggered if the Nasdaq bid price stays below US$1.00 for three consecutive trading days. The split ratio would be selected from 10-for-1 down to 2-for-1, aiming to keep at least 500,000 publicly held shares. A proposal also seeks to increase authorized share capital to 1,000,000,000 shares, including 999,400,000 Class A shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ucommune International Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-107735), on October 08, 2026, and is solely responsible for the information contained therein.
- Ucommune will hold an extraordinary general meeting in Beijing on Nov. 9, 2026.
- Shareholders will vote on a potential reverse share split triggered if the Nasdaq bid price stays below US$1.00 for three consecutive trading days.
- The split ratio would be selected from 10-for-1 down to 2-for-1, aiming to keep at least 500,000 publicly held shares.
- A proposal also seeks to increase authorized share capital to 1,000,000,000 shares, including 999,400,000 Class A shares.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
